Everly Health, Inc, 823 Congress Ave., Suite 1200, Austin, TX, 78701, USA.
University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
BMC Infect Dis. 2022 May 9;22(1):443. doi: 10.1186/s12879-022-07377-4.
Diagnostic testing accessibility and asymptomatic transmission of SARS-CoV-2 present major challenges for curbing and preventing community prevalence of COVID-19. At-home sample collection for molecular testing provides a convenient and effective solution for disease containment and prevention.
This is a retrospective, cross-sectional, case-control study. Our primary aim was to determine the prevalence and relative risk of SARS-CoV-2 among asymptomatic versus symptomatic individuals using at-home sample collection kits for diagnosis. Participants included adults from across the United States who completed a COVID-19 Home Collection kit between May 2020 and September 2021. Main measurements included self-reported symptoms and at-home self-collected anterior nasal swab RT-PCR test results for SARS-CoV-2.
Data from 282,831 individuals were included in this analysis. The overall SARS-CoV-2 prevalence of at-home test takers was low compared to national averages during this period (3.28% vs. 7.68%). Those reporting no symptoms were at lower risk of positive test results compared to those with symptoms (risk ratio: 0.080, 95% CI, 0.078-0.082). However, of all positive SARS-CoV-2 tests, 48.75% were from individuals reporting no symptoms at the time of testing.
We conclude that at-home sample collection is a viable option and potentially important strategy for improving access to testing, detecting asymptomatic cases, and curbing preventable transmission of COVID-19.
诊断检测的可及性和 SARS-CoV-2 的无症状传播对遏制和预防 COVID-19 在社区中的流行构成了重大挑战。用于分子检测的家庭样本采集为疾病的控制和预防提供了一种便捷有效的解决方案。
这是一项回顾性、横断面、病例对照研究。我们的主要目的是使用用于诊断的家庭样本采集试剂盒,确定无症状个体与有症状个体之间 SARS-CoV-2 的患病率和相对风险。参与者包括来自美国各地的成年人,他们在 2020 年 5 月至 2021 年 9 月期间完成了 COVID-19 家庭采集试剂盒。主要测量包括自我报告的症状和家庭自我采集的前鼻拭子 RT-PCR 检测 SARS-CoV-2 的结果。
本分析共纳入 282831 名个体的数据。与同期全国平均水平相比,家庭检测者的 SARS-CoV-2 总体患病率较低(3.28% vs. 7.68%)。与有症状者相比,无症状者的阳性检测结果风险较低(风险比:0.080,95%CI,0.078-0.082)。然而,在所有 SARS-CoV-2 阳性检测中,48.75%来自于检测时无症状的个体。
我们的结论是,家庭样本采集是一种可行的选择,也是提高检测可及性、发现无症状病例和遏制 COVID-19 可预防传播的潜在重要策略。